InvestSMART

Clinuvel Pharmaceuticals Limited (ASX: CUV) - Announcements

- Current share price for CUV : $8.260

ASX company news and announcements for Clinuvel Pharmaceuticals Limited (CUV) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clinuvel Pharmaceuticals Limited (CUV) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clinuvel Pharmaceuticals Limited (CUV), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clinuvel Pharmaceuticals Limited (CUV)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$417 Half Year Results Webinar Recording 23 Feb 2024 10:01AM $14.580 $8.260 fallen by 43.35%
$417 CLINUVEL Delivers Increased Revenues, Solid Earnings 22 Feb 2024 10:11AM $15.430 $8.260 fallen by 46.47%
$417 CUV Appendix 4D Half Year Report 22 Feb 2024 9:48AM $16.290 $8.260 fallen by 49.29%
$417 Director Resignation 21 Feb 2024 3:27PM $16.300 $8.260 fallen by 49.32%
$417 CEO Letter to Shareholders 16 Feb 2024 10:20AM $15.920 $8.260 fallen by 48.12%
$417 Half Year Results Investor Webinar 16 Feb 2024 9:46AM $15.790 $8.260 fallen by 47.69%
$417 Change in substantial holding 31 Jan 2024 8:26AM $15.450 $8.260 fallen by 46.54%
$417 CLINUVEL Newsletter 1 - January 2024 16 Jan 2024 9:23AM $15.990 $8.260 fallen by 48.34%
$417 Chair Elect Letter 14 Dec 2023 10:14AM $16.710 $8.260 fallen by 50.57%
$417 Change to Registered Office 7 Dec 2023 2:59PM $17.920 $8.260 fallen by 53.91%
$417 Notification of cessation of securities - CUV 27 Nov 2023 3:59PM $17.340 $8.260 fallen by 52.36%
$417 Change of Director's Interest Notice 27 Nov 2023 1:43PM $17.240 $8.260 fallen by 52.09%
$417 Application for quotation of securities - CUV 27 Nov 2023 12:11PM $17.230 $8.260 fallen by 52.06%
$417 CLINUVEL Newsletter V - November 2023 24 Nov 2023 10:23AM $16.800 $8.260 fallen by 50.83%
$417 Sydney Vitiligo Presentation 10 Nov 2023 10:05AM $16.160 $8.260 fallen by 48.89%
$417 Final Director's Interest Notice 2 Nov 2023 9:28AM $14.710 $8.260 fallen by 43.85%
$417 CLINUVEL Appoints New Chair 31 Oct 2023 1:24PM $14.770 $8.260 fallen by 44.08%
$417 Results of Meeting 31 Oct 2023 12:12PM $14.900 $8.260 fallen by 44.56%
$417 CEO Presentation AGM 31 Oct 2023 11:19AM $14.800 $8.260 fallen by 44.19%
$417 Chair's Address 31 Oct 2023 10:04AM $14.870 $8.260 fallen by 44.45%
$417 CLINUVEL starts global Phase III vitiligo study 18 Oct 2023 10:08AM $15.800 $8.260 fallen by 47.72%
$417 CLINUVEL Newsletter IV - October 2023 6 Oct 2023 9:56AM $14.760 $8.260 fallen by 44.04%
$417 Board Changes after AGM 29 Sep 2023 10:17AM $14.850 $8.260 fallen by 44.38%
$417 Notice of Annual General Meeting/Proxy Form 29 Sep 2023 9:34AM $14.900 $8.260 fallen by 44.56%
$417 Change of Director's Interest Notice 20 Sep 2023 8:32AM $15.640 $8.260 fallen by 47.19%

201 - 225 of 873 results

Page 9 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.